BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
159.1 EUR
+0.2 (+0.13%)
Overall IDP gets a fundamental rating of 5 out of 10. We evaluated IDP against 83 industry peers in the Biotechnology industry. IDP has an excellent financial health rating, but there are some minor concerns on its profitability. IDP has a bad growth rate and is valued cheaply. These ratings would make IDP suitable for value investing!
1. Profitability
1.1 Basic Checks
IDP had positive earnings in the past year.
In the past year IDP had a positive cash flow from operations.
Each year in the past 5 years IDP has been profitable.
Each year in the past 5 years IDP had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 5.51%, IDP is doing good in the industry, outperforming 78.31% of the companies in the same industry.
The Return On Equity of IDP (8.84%) is better than 79.52% of its industry peers.
IDP's Return On Invested Capital of 9.70% is amongst the best of the industry. IDP outperforms 86.75% of its industry peers.
IDP had an Average Return On Invested Capital over the past 3 years of 10.57%. This is in line with the industry average of 11.63%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
IDP has a Profit Margin of 15.98%. This is amongst the best in the industry. IDP outperforms 80.72% of its industry peers.
In the last couple of years the Profit Margin of IDP has declined.
IDP has a better Operating Margin (28.50%) than 86.75% of its industry peers.
IDP's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 75.24%, IDP is doing good in the industry, outperforming 63.86% of the companies in the same industry.
In the last couple of years the Gross Margin of IDP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
IDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
IDP has more shares outstanding than it did 1 year ago.
IDP has less shares outstanding than it did 5 years ago.
IDP has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.37 indicates that IDP is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.37, IDP is in the better half of the industry, outperforming 73.49% of the companies in the same industry.
IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 2.78, IDP is doing good in the industry, outperforming 79.52% of the companies in the same industry.
A Debt/Equity ratio of 0.35 indicates that IDP is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.35, IDP perfoms like the industry average, outperforming 53.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.37 |
ROIC/WACC1.17
WACC8.28%
2.3 Liquidity
A Current Ratio of 2.72 indicates that IDP has no problem at all paying its short term obligations.
IDP has a Current ratio (2.72) which is in line with its industry peers.
IDP has a Quick Ratio of 2.04. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.04, IDP is in line with its industry, outperforming 48.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
IDP shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
Measured over the past years, IDP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
The Revenue has been growing slightly by 4.77% in the past year.
Measured over the past years, IDP shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
The Earnings Per Share is expected to grow by 0.56% on average over the next years.
IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.63% yearly.
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 11.09, which indicates a very decent valuation of IDP.
IDP's Price/Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 91.57% of the companies in the same industry.
IDP is valuated cheaply when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 12.02 indicates a correct valuation of IDP.
IDP's Price/Forward Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 95.18% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.88, IDP is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.09 | ||
| Fwd PE | 12.02 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 86.75% of the companies listed in the same industry.
IDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IDP is cheaper than 92.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.04 | ||
| EV/EBITDA | 8.12 |
4.3 Compensation for Growth
The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
5. Dividend
5.1 Amount
IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IDP (1/8/2026, 7:00:00 PM)
159.1
+0.2 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap23.34B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts74.29
Price Target155.43 (-2.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)0.32%
PT rev (3m)4.91%
EPS NQ rev (1m)-1%
EPS NQ rev (3m)-54.86%
EPS NY rev (1m)0.27%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.3%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.09 | ||
| Fwd PE | 12.02 | ||
| P/S | 2.71 | ||
| P/FCF | 12.04 | ||
| P/OCF | 11.11 | ||
| P/B | 1.5 | ||
| P/tB | 11.43 | ||
| EV/EBITDA | 8.12 |
EPS(TTM)14.34
EY9.01%
EPS(NY)13.24
Fwd EY8.32%
FCF(TTM)13.21
FCFY8.3%
OCF(TTM)14.33
OCFY9%
SpS58.77
BVpS106.31
TBVpS13.92
PEG (NY)N/A
PEG (5Y)N/A
Graham Number185.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.37 |
F-Score5
WACC8.28%
ROIC/WACC1.17
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year6.14%
EBIT Next 3Y0.99%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
What is the valuation status for IDP stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
What is the financial health of BIOGEN INC (IDP.DE) stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.54% in the next year.